11/29/2012

RQx Pharmaceuticals was born after researcher Floyd Romesberg and investor Court Turner happened to strike up a conversation in a local coffee shop. Romesberg is developing arylomycin to work against gram-negative and -positive bacteria, potentially leading to a new broad-spectrum antibiotic. Turner's company, Avalon Ventures, provided the first $1 million for Romesberg to start a new company, and Correlation Ventures has since joined as a venture investor.

Full Story:
Xconomy

Related Summaries